[HTML][HTML] 3MO Comprehensive biomarkers (BMS) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: A …
F Barlesi, L Greillier, F Monville, CA Valette… - Immuno-Oncology …, 2022 - esmoiotech.org
Background Prediction of ICIs efficacy in combination with chemotherapy remains an unmet
need in patients (pts) with advanced NSCLC. The PIONeeR trial aims to predict …
need in patients (pts) with advanced NSCLC. The PIONeeR trial aims to predict …
[HTML][HTML] 782-C Regulatory T-cell tumor infiltration is associated to better outcome in advanced NSCLC patients under≥ 2nd line anti-PD1/L1 monotherapy in the …
M Landri, M Vasseur, F Monville, V Leca, C Hamdad… - 2023 - jitc.bmj.com
Background Immune checkpoint inhibitors (ICIs) are associated with long-term survival in~
20% of advanced NSCLC patients while biological mechanisms triggering resistance are …
20% of advanced NSCLC patients while biological mechanisms triggering resistance are …
[HTML][HTML] 460 Spatial distribution of infiltrating T lymphocytes with Immunoscore® CR T cells exhaustion test helps stratification of NSCLC patients treated with PD1 …
V Leca, A Kassambara, L Ghezali, P Outters… - 2021 - jitc.bmj.com
Background PD1/L1 Immune Checkpoint Inhibitors (ICI) have significantly improved long-
term outcome in about 20% of advanced Non Small Cells Lung Cancer (NSCLC) patients …
term outcome in about 20% of advanced Non Small Cells Lung Cancer (NSCLC) patients …
Abstract LB120: Comprehensive biomarkers analysis to explain resistances to PD1-L1 ICIs: The precision immuno-oncology for advanced non-small cell lung cancer …
L Greillier, F Monville, V Leca, F Vely, S Garcia… - Cancer Research, 2022 - AACR
Abstract Background: Resistance to PD1/L1 immune checkpoint inhibitors (ICIs) in
advanced NSCLC patients is observed in about 80% of individuals with no robust predictive …
advanced NSCLC patients is observed in about 80% of individuals with no robust predictive …
[HTML][HTML] 701 Brightplex® TCE and brightplex® MDSC assays combination improves advanced NSCLC patients' stratification under anti-PD1/L1 immunotherapy in the …
L Ghezali, M Landri, F Monville, V Leca, T Vasse… - 2022 - jitc.bmj.com
Background Immune Checkpoint Inhibitors (ICIs) are associated with long-term survival in~
20% of advanced NSCLC patients while biological mechanisms triggering resistance are …
20% of advanced NSCLC patients while biological mechanisms triggering resistance are …
[CITATION][C] Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a …
F Barlesi, F Monville, C Audigier-Valette, S Martinez… - ESMO Immuno-Oncology …, 2022
[CITATION][C] Infections urinaires en EHPAD: impact du déploiement d'un kit antibiotique régional sur les taux de résistances bactériennes
M Le Ray - 2017